Study ID Study Title Species Institute
ST000414Metabolomics-based screening of the Malaria Box reveals both novel and established mechanisms of actionPlasmodium falciparumMonash Institute of Pharmaceutical Sciences
ST000441Metabolomic Profiling of the Malaria Box Reveals Antimalarial Target PathwaysPlasmodium falciparumPennsylvania State University
ST000546Multi-omics based identification of specific biochemical changes associated with PfKelch13-mutant artemisinin resistant PlasmodiumPlasmodium falciparumMonash University
ST001033Determination of mode of action of anti-malalrial drugs using untargeted metabolomicsPlasmodium falciparumMonash University
ST001149Plasmodium Niemann-Pick Type C1-Related Protein is a Druggable Target Required for Parasite Membrane HomeostasisPlasmodium falciparumPennsylvania State University
ST001175Multi-omics analysis demonstrates unique mode of action of a potent new antimalarial compound, JPC-3210, against Plasmodium falciparumPlasmodium falciparumMonash University
ST001188P. falciparum infected erythrocytesPlasmodium falciparumUniversity of Melbourne
ST001201Peroxide antimalarial treatment timecourse on trophozoite-stage P. falciparum parasitesPlasmodium falciparumMonash University
ST001202Peroxide antimalarial treatment timecourse on ring-stage P. falciparum parasitesPlasmodium falciparumMonash University
ST001204Peroxide antimalarial extended treatment timecourse on trophozoite-stage P. falciparum parasitesPlasmodium falciparumMonash University
ST001205Peroxide antimalarial treatment of K13-mutant and -wildtype P. falciparum parasitesPlasmodium falciparumMonash University
ST001232Combining stage - specificity and metabolomic profiling to advance drug discovery for malariaPlasmodium falciparumPennsylvania State University
ST001238P falciparum asexual metabolomics following drug treatment (part-I)Plasmodium falciparumPennsylvania State University
ST001279K13 mutations driving artemisinin resistance rewrite Plasmodium falciparum’s programmed intra-erythrocytic development and transform mitochondrial physiologyPlasmodium falciparumPennsylvania State University
ST001315Retargeting azithromycin-like compounds as antimalarials with dual modalityPlasmodium falciparumMonash University
ST001652Atypical Molecular Basis for Drug Resistance to Mitochondrial AQ: A Function Inhibitors in Plasmodium falciparumPlasmodium falciparumU.S. Food & Drug Administration
ST001660Plasmodium falciparum metabolomics as a result of treatment with putative acetyl-CoA synthetase inhibitorsPlasmodium falciparumPennsylvania State University
ST001985Profiling Plasmodium falciparum parasites and human red blood cells after treatment with MMV693183Plasmodium falciparumPennsylvania State University
ST002011The anticancer human mTOR inhibitor MLN0128/Sapanisertib with potent multistage in vitro antiplasmodium activity and in vivo antimalarial efficacy in a humanised mouse model is an inhibitor of multiple Plasmodium falciparum kinases.Plasmodium falciparumPennsylvania State University
ST002024Plasmodium falciparum stable-isotope carbon labeling to explore metabolic consequences of keto–acid dehydrogenase disruptionPlasmodium falciparumPennsylvania State University
ST002078Multiple modes of interfering with the activity of Plasmodium falciparum cytoplasmic isoleucyl-tRNA synthetase illustrate the enzyme is a promising antimalarial target.Plasmodium falciparumPennsylvania State University
ST002106Genetic and chemical validation of Plasmodium falciparum aminopeptidase PfA-M17 as a drug target in the hemoglobin digestion pathway (Part 1)Plasmodium falciparumMonash University
ST002107Genetic and chemical validation of Plasmodium falciparum aminopeptidase PfA-M17 as a drug target in the hemoglobin digestion pathway (Part 2)Plasmodium falciparumMonash University
ST002108Genetic and chemical validation of Plasmodium falciparum aminopeptidase PfA-M17 as a drug target in the hemoglobin digestion pathway (Part 3)Plasmodium falciparumMonash University
ST002181Piperaquine-resistant PfCRT mutations differentially impact drug transport, hemoglobin catabolism and parasite physiology in Plasmodium falciparum asexual blood stages.Plasmodium falciparumPennsylvania State University
ST002309Targeting malaria parasites with novel derivatives of azithromycinPlasmodium falciparumMonash University
ST002792Chemoproteomics validates selective targeting of Plasmodium M1 alanyl aminopeptidase as a cross-species strategy to treat malariaPlasmodium falciparumMonash University
ST002926Multi-“omics” analysis reveals the orphan P. falciparum protein kinase PfPK8 regulates multi-gene family expressionPlasmodium falciparumMonash University
ST003144On-target, dual aminopeptidase inhibition provides cross-species antimalarial activityPlasmodium falciparumMonash University
ST003160New class of heterospirocyclic compounds present strong and rapid activity against artemisinin- and multidrug-resistant P. falciparum parasitesPlasmodium falciparumMonash University
ST003179Property and Activity Refinement of Dihydroquinazolinone-3-carboxamides as Orally Efficacious Antimalarials that Target PfATP4Plasmodium falciparumMonash University
ST003224The Ataxia-Telangiectasia Mutated Kinase Inhibitor AZD0156 is a Potent Inhibitor of Plasmodium Phosphatidylinositol 4-Kinase and is an Attractive Candidate for Repositioning Against MalariaPlasmodium falciparumPennsylvania State University
ST003562Multiple, redundant carboxylic acid transporters support mitochondrial metabolism in Plasmodium falciparumPlasmodium falciparumPennsylvania State University
ST003565Metaboloomics analysis of the antimalarial compound WEHI-1888504 (aka compound 59) in Plasmodium falciparum (3D7) infected red blood cellsPlasmodium falciparumMonash University
ST003642Hexosamine Biosynthesis Disruption Impairs GPI Production and Arrests Plasmodium falciparum Growth at Schizont StagesPlasmodium falciparumPennsylvania State University
ST003902Plasmodium falciparum plasmepsin copy number and piperaquine treatment have no effect of hemoglobin digestionPlasmodium falciparumPennsylvania State University
ST003904Plasmodium falciparum plasmepsin copy number and piperaquine treatment have no effect of hemoglobin digestion - Negative ModePlasmodium falciparumPennsylvania State University
ST003906Neither Plasmodium falciparum Plasmepsin Copy Number Nor Piperaquine Treatment Impact Hemoglobin DigestionPlasmodium falciparumPennsylvania State University
ST004194PfK13-associated artemisinin resistance slows drug activation and enhances antioxidant defence, which can be overcome with sulforaphanePlasmodium falciparumMonash University
ST004290Metabolomics characterisation of Plasmodium falciparum response to plasmepsin V peptidomimetic inhibitors - 5 hour treatmentPlasmodium falciparumMonash University
ST004291Metabolomics analysis of Plasmodium falciparum asexual-stage parasites treated with plasmepsin V peptidomimetics - 16 hour treatmentPlasmodium falciparumMonash University

Return to search page
  logo